Dr. Burtness on Immunotherapy and Radioresistance in Head and Neck Cancer

Barbara Burtness, MD
Published: Wednesday, Jul 19, 2017



Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy in patients with head and neck cancer who have radioresistance.

In an investigator-initiated trial at Yale Cancer Center, patients with persistent disease after radiation are being exposed to pembrolizumab (Keytruda) in hope of initiating an immune response prior to salvage therapy.
 


Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy in patients with head and neck cancer who have radioresistance.

In an investigator-initiated trial at Yale Cancer Center, patients with persistent disease after radiation are being exposed to pembrolizumab (Keytruda) in hope of initiating an immune response prior to salvage therapy.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x